MolecuLight announces Health Canada approval for the MolecuLight i:X, its first diagnostic medical imaging device for wound care

October 20, 2015 -MolecuLight Inc. has been authorized to sell the MolecuLight i:X by Health Canada

TORONTO, Oct. 20, 2015 /CNW/ – MolecuLight ® Inc. has been authorized to sell the MolecuLight i:X by Health Canada. The approval will allow the company to begin selling the product throughout Canada.  MolecuLight i:X is a novel, handheld fluorescence

MolecuLight receives $990,000 from FedDev Ontario to complete commercialization of a new clinical wound imaging technology

November 28, 2014 -This important financial support will allow MolecuLight to accelerate commercialization

This important financial support will allow MolecuLight to accelerate commercialization of its unique patented handheld fluorescence-imaging platform, which will enable clinicians to detect bacteria in chronic wounds, in real-time and at the point-of-care. MolecuLight’s technology addresses an important problem in

MolecuLight announces research collaboration to advance point-of-care bacterial imaging device

November 7, 2014 -

Posted on November 07 , 2014

MolecuLight Inc. (Toronto, Canada) announced today a multi-project based research agreement with the University Health Network (UHN, Toronto, Canada) aimed at advancing their new handheld optical imaging technology enabling real-time bacterial imaging in wounds at the point-of-care.

Under the terms of the Agreement, MolecuLight Inc. will